PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer
Background: The polypyrimidine tract-binding protein (PTBP) nuclear ribonucleoprotein family of proteins, including PTBP1, PTBP2 and PTBP3, regulate the process of cell proliferation, differentiation, apoptosis and carcinogenesis. PTBPs exhibit oncogenic effects in certain tumors. However, the role...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2022.968458/full |
| _version_ | 1828147521792245760 |
|---|---|
| author | Chen Chen Anquan Shang Yuting Gao Jingjuan Huang Gege Liu William C. Cho Dong Li |
| author_facet | Chen Chen Anquan Shang Yuting Gao Jingjuan Huang Gege Liu William C. Cho Dong Li |
| author_sort | Chen Chen |
| collection | DOAJ |
| description | Background: The polypyrimidine tract-binding protein (PTBP) nuclear ribonucleoprotein family of proteins, including PTBP1, PTBP2 and PTBP3, regulate the process of cell proliferation, differentiation, apoptosis and carcinogenesis. PTBPs exhibit oncogenic effects in certain tumors. However, the role of PTBPs in pan-cancer remains unclear. Our study examined the clinical significance and mechanism of PTBPs in pan-cancer.Methods: We compared the expression of PTBPs in paired and unpaired tissue samples from the Cancer Genome Atlas (TCGA) database. Univariate and multivariate Cox regression, Kaplan–Meier curves, and time-dependent receiver operating characteristic (ROC) curves were used to assess the prognostic significance of PTBPs in pan-cancer. The cBioPortal database also identified genomic abnormalities in PTBPs. TISIDB, TCGA, and Cellminer were used to investigate the relationship between PTBP expression and immune subtypes, immune checkpoint (ICP) genes, tumor mutational burden (TMB), microsatellite instability (MSI), tumor-infiltrating immune cells, and chemosensitivity. cBioPortal was used to search for PTBP co-expressing genes in pan-cancer, and GO and KEGG enrichment analyses were performed to search for PTBP-related signaling pathways.Results:PTBPs were shown to be widely upregulated in human tumor tissues. PTBP1 showed good prognostic value in ACC, KIRP, and LGG; PTBP2 in ACC and KICH; and PTBP3 in ACC, LGG, and PAAD, with AUC >0.7. PTBPs were differentially expressed in tumor immune subtypes and had a strong correlation with tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME). In addition, PTBP expressions were related to ICP, TMB, and MSI, suggesting that these three PTBPs may be potential tumor immunotherapeutic targets and predict the efficacy of immunotherapy. Enrichment analysis of co-expressed genes of PTBPs showed that they may be involved in alternative splicing, cell cycle, cellular senescence, and protein modification.Conclusion: PTBPs are involved in the malignant progression of tumors. PTBP1, PTBP2 and PTBP3 may be potential biomarkers for prognosis and immunotherapy in pan-cancer and may be novel immunotherapeutic targets. |
| first_indexed | 2024-04-11T21:01:39Z |
| format | Article |
| id | doaj.art-1da6d53576f74f9c89a070eb8b4f52b4 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-04-11T21:01:39Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-1da6d53576f74f9c89a070eb8b4f52b42022-12-22T04:03:28ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2022-08-01910.3389/fmolb.2022.968458968458PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancerChen Chen0Anquan Shang1Yuting Gao2Jingjuan Huang3Gege Liu4William C. Cho5Dong Li6Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR, ChinaDepartment of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, ChinaBackground: The polypyrimidine tract-binding protein (PTBP) nuclear ribonucleoprotein family of proteins, including PTBP1, PTBP2 and PTBP3, regulate the process of cell proliferation, differentiation, apoptosis and carcinogenesis. PTBPs exhibit oncogenic effects in certain tumors. However, the role of PTBPs in pan-cancer remains unclear. Our study examined the clinical significance and mechanism of PTBPs in pan-cancer.Methods: We compared the expression of PTBPs in paired and unpaired tissue samples from the Cancer Genome Atlas (TCGA) database. Univariate and multivariate Cox regression, Kaplan–Meier curves, and time-dependent receiver operating characteristic (ROC) curves were used to assess the prognostic significance of PTBPs in pan-cancer. The cBioPortal database also identified genomic abnormalities in PTBPs. TISIDB, TCGA, and Cellminer were used to investigate the relationship between PTBP expression and immune subtypes, immune checkpoint (ICP) genes, tumor mutational burden (TMB), microsatellite instability (MSI), tumor-infiltrating immune cells, and chemosensitivity. cBioPortal was used to search for PTBP co-expressing genes in pan-cancer, and GO and KEGG enrichment analyses were performed to search for PTBP-related signaling pathways.Results:PTBPs were shown to be widely upregulated in human tumor tissues. PTBP1 showed good prognostic value in ACC, KIRP, and LGG; PTBP2 in ACC and KICH; and PTBP3 in ACC, LGG, and PAAD, with AUC >0.7. PTBPs were differentially expressed in tumor immune subtypes and had a strong correlation with tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME). In addition, PTBP expressions were related to ICP, TMB, and MSI, suggesting that these three PTBPs may be potential tumor immunotherapeutic targets and predict the efficacy of immunotherapy. Enrichment analysis of co-expressed genes of PTBPs showed that they may be involved in alternative splicing, cell cycle, cellular senescence, and protein modification.Conclusion: PTBPs are involved in the malignant progression of tumors. PTBP1, PTBP2 and PTBP3 may be potential biomarkers for prognosis and immunotherapy in pan-cancer and may be novel immunotherapeutic targets.https://www.frontiersin.org/articles/10.3389/fmolb.2022.968458/fullbiomarkersimmunotherapypan-cancerpolypyrimidine tract-binding proteinsprognosis |
| spellingShingle | Chen Chen Anquan Shang Yuting Gao Jingjuan Huang Gege Liu William C. Cho Dong Li PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer Frontiers in Molecular Biosciences biomarkers immunotherapy pan-cancer polypyrimidine tract-binding proteins prognosis |
| title | PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer |
| title_full | PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer |
| title_fullStr | PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer |
| title_full_unstemmed | PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer |
| title_short | PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer |
| title_sort | ptbps an immunomodulatory related prognostic biomarker in pan cancer |
| topic | biomarkers immunotherapy pan-cancer polypyrimidine tract-binding proteins prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2022.968458/full |
| work_keys_str_mv | AT chenchen ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT anquanshang ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT yutinggao ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT jingjuanhuang ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT gegeliu ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT williamccho ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer AT dongli ptbpsanimmunomodulatoryrelatedprognosticbiomarkerinpancancer |